Aquestive Therapeutics Inc. (NASDAQ:AQST) shares, rose in value on Thursday, 05/25/23, with the stock price down by -2.63% to the previous day’s close as strong demand from buyers drove the stock to $2.22.
Actively observing the price movement in the last trading, the stock closed the session at $2.28, falling within a range of $2.17 and $2.38. The value of beta (5-year monthly) was 2.75. Referring to stock’s 52-week performance, its high was $2.69, and the low was $0.62. On the whole, AQST has fluctuated by 77.60% over the past month.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
With the market capitalization of Aquestive Therapeutics Inc. currently standing at about $115.00 million, investors are eagerly awaiting this quarter’s results, scheduled for Jul 31, 2023 – Aug 04, 2023. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.1, which is expected to increase to -$0.1 for fiscal year -$0.26 and then to about -$0.57 by fiscal year 2024. Data indicates that the EPS growth is expected to be 76.80% in 2024, while the next year’s EPS growth is forecast to be -119.20%.
Analysts have estimated the company’s revenue for the quarter at $11.06 million, with a low estimate of $10.68 million and a high estimate of $12 million. According to the average forecast, sales growth in current quarter could jump down -16.60%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2024, the company’s y-o-y revenues would reach $43.48 million, representing a decrease of -8.80% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 1 upward and no downward review(s) in last seven days. We see that AQST’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
#####
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of AQST currently trading nearly 10.72% and 53.14% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 60.86, while the 7-day volatility ratio is showing 12.19% which for the 30-day chart, stands at 14.32%. Furthermore, Aquestive Therapeutics Inc. (AQST)’s beta value is 2.67, and its average true range (ATR) is 0.24.
#####
Data on historical trading for Aquestive Therapeutics Inc. (NASDAQ:AQST) indicates that the trading volumes over the past 10 days have averaged 1.08 million and over the past 3 months, they’ve averaged 520.05K. According to company’s latest data on outstanding shares, there are 55.63 million shares outstanding.
Nearly 0.40% of Aquestive Therapeutics Inc.’s shares belong to company insiders and institutional investors own 29.60% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.84 million shares as on Apr 27, 2023, resulting in a short ratio of 6.31. According to the data, the short interest in Aquestive Therapeutics Inc. (AQST) stood at 3.29% of shares outstanding as of Apr 27, 2023; the number of short shares registered in Mar 30, 2023 reached 1.85 million. The stock has risen by 146.09% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AQST stock heading into the next quarter.
